GSK plc (BVMF:G1SK34)

Market Cap	626.56B +48.1%
Revenue (ttm)	242.17B +4.1%
Net Income	42.37B +122.0%
EPS	10.29 +123.2%
Shares Out	n/a
PE Ratio	14.79
Forward PE	11.96
Dividend	1.80 (2.87%)
Ex-Dividend Date	Nov 13, 2025

Volume	89
Average Volume	115
Open	61.00
Previous Close	59.72
Day's Range	61.00 - 62.68
52-Week Range	39.50 - 62.68
Beta	0.27
RSI	81.30
Earnings Date	Feb 4, 2026

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1715
• Employees: 68,629
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: G1SK34

Financial Performance

In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.

Financial numbers in GBP